Interim FDG-PET/CT in Hodgkin Lymphoma: What Are We Actually Looking At?

Acta Oncologica - United Kingdom
doi 10.1080/0284186x.2018.1441541
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Interim FDG-PET Does Not Predict Outcome in Advanced-Stage Hodgkin Lymphoma Patients Treated With BEACOPP

British Journal of Haematology
Hematology
2018English

Fact Sheet About Interim and End-Of-Treatment 18 F-FDG PET/CT in Lymphoma

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2017English

Hodgkin Lymphoma Classification: Are We at a Crossroads?

Cancer
Cancer ResearchOncology
2017English

Hodgkin Lymphoma: Is There Really a Need for Interim and End-Of-Treatment FDG-PET Evaluations?

British Journal of Haematology
Hematology
2016English

Reply: Fact Sheet About Interim and End-Of-Treatment 18 F-FDG PET/CT in Lymphoma

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2017English

Prognostic Value of Pre-Transplant Pet/Ct in Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

What Parameters From 18f-FDG PET/CT Are Useful in Evaluation of Adrenal Lesions?

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2014English

Do We Need FDG-PET/CT to Assess Atherosclerosis?

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2016English

Interim FDG-PET Has No Value in Selecting Patients Who Require Treatment Modification in Both Early- And Advanced-Stage Hodgkin Lymphoma

British Journal of Haematology
Hematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy